PROCEPT BioRobotics Corp — Director's Dealing 2024

Nov 8, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROCEPT BioRobotics Corp (PRCT)
CIK: 0001588978
Period of Report: 2024-11-05

Reporting Person: Desai Antal Rohit (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-05	Common Stock	J	660302	—	Disposed	0	Indirect
2024-11-05	Common Stock	J	172016	—	Disposed	0	Indirect
2024-11-05	Common Stock	J	62944	—	Disposed	0	Indirect
2024-11-05	Common Stock	S	7566	$95.3828	Disposed	256797	Indirect
2024-11-05	Common Stock	S	11756	$96.4897	Disposed	245041	Indirect
2024-11-05	Common Stock	S	11487	$97.1687	Disposed	233554	Indirect
2024-11-05	Common Stock	S	2191	$98.4295	Disposed	231363	Indirect
2024-11-06	Common Stock	S	9403	$95.6767	Disposed	221960	Indirect
2024-11-06	Common Stock	S	2678	$96.5713	Disposed	219282	Indirect
2024-11-06	Common Stock	S	17150	$97.593	Disposed	202132	Indirect
2024-11-06	Common Stock	S	3769	$98.2909	Disposed	198363	Indirect
2024-11-07	Common Stock	S	6992	$94.4229	Disposed	191371	Indirect
2024-11-07	Common Stock	S	16272	$95.3282	Disposed	175099	Indirect
2024-11-07	Common Stock	S	10236	$96.0339	Disposed	164863	Indirect
2024-11-07	Common Stock	S	500	$97.54	Disposed	164363	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	6865	Direct

Footnotes

F1: On November 5, 2024, White Tailed Ptarmigan, LP distributed shares on a pro rata basis, for no consideration, including 51,245 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13.

F2: CPMG, Inc. is the general partner and investment manager of each of White Tailed Ptarmigan, LP, Kestrel Fund, L.P. and Mallard Fund, L.P. (collectively, the "CPMG Funds"). Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by the CPMG Funds. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by the CPMG Funds except to the extent of any pecuniary interest therein.

F3: On November 5, 2024, Mallard Fund, L.P. distributed all of its remaining shares on a pro rata basis, for no consideration, including 8,511 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13.

F4: Includes shares previously held indirectly through White Tailed Ptarmigan, LP, which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13.

F5: On November 5, 2024, Kestrel Fund, L.P. distributed all of its remaining shares on a pro rata basis, for no consideration, including 3,316 shares that were distributed in transactions exempt from Section 16 under Rule 16a-13.

F6: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2024.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.64 to $95.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F8: Includes shares previously held indirectly through Mallard Fund, L.P., which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13.

F9: Includes shares previously held indirectly through Kestrel Fund, L.P., which were distributed on a pro rata basis, for no consideration, on November 5, 2024, in a transaction exempt from Section 16 under Rules 16a-9 and 16a-13.

F10: Mr. Desai and his spouse serve as co-trustees of The 2:22 DNA Trust. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by The 2:22 DNA Trust except to the extent of any pecuniary interest therein.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.91 to $96.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.91 to $97.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.94 to $98.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.07 to $96.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.07 to $97.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.07 to $98.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.09 to $98.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.75 to $94.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.78 to $95.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.78 to $96.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.